AstraZeneca PLC (AZN.L)
LSE - LSE Delayed price. Currency in GBp
Add to watchlist
As of 12:51PM BST. Market open.
| Previous close | 10,250.00 |
| Open | 10,326.00 |
| Bid | 10,492.00 x 0 |
| Ask | 10,494.00 x 0 |
| Day's range | 10,308.00 - 10,500.00 |
| 52-week range | 6,499.80 - 11,000.00 |
| Volume | |
| Avg. volume | 2,861,525 |
| Market cap | 162.569B |
| Beta (5Y monthly) | 0.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -58.30 |
| Earnings date | 29 Apr 2022 |
| Forward dividend & yield | 2.10 (2.05%) |
| Ex-dividend date | 24 Feb 2022 |
| 1y target est | 111.72 |
- Zacks
Merck (MRK) Outperforms Industry This Year So Far: Here's Why
Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.
- Zacks
AstraZeneca (AZN) Inks Deal to Develop COVID-19 Antibodies
AstraZeneca (AZN) partners with a U.K.-based biotech company to develop monoclonal antibodies targeting the COVID-causing virus.
- Business Wire
PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed Rescue Medicine, Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients With Asthma
WILMINGTON, Del., May 15, 2022--Full results from the positive MANDALA Phase III trial showed that PT027 (albuterol/budesonide) at two different strengths of budesonide, an inhaled corticosteroid (ICS), used as an as-needed rescue medicine, demonstrated a statistically significant reduction in the risk of a severe exacerbation versus albuterol rescue in patients with moderate to severe asthma.1,2
© 2022 Yahoo. All rights reserved.
